Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378769 | 0.85 | TNKS2 (0.75) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL9724162 | 0.80 | LMNA (0.67) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL31475465 | 0.80 | LMNA (0.67) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL4062622 | 0.79 | KDM4E (0.59) | LMNAKEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL28834693 | 0.79 | KDR (0.51) | LMNAKEAP1NFE2L2TNKS2KDM4E | |
| SCHEMBL1420703 | 0.77 | LMNA (0.62) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL4482742 | 0.77 | LMNA (0.62) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL11097088 | 0.77 | GAA (0.73) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL1224662 | 0.77 | LMNA (0.62) | LMNATNKS2KDM4EALDH1A1GAA | |
| SCHEMBL3151814 | 0.77 | LMNA (1.00) | LMNATNKS2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-9394263-B2 | Substituted hetero-azepinones | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2882725-A1 | SUBSTITUTED HETERO-AZEPINONES | F. Hoffmann-La Roche AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023708-A1 | SUBSTITUTED HETERO-AZEPINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| US-4187310-A | ANTIINFLAMMATORY AGENT, ANALGESICS, ENZYME INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-02-05 | — | — | US | disclosed |
| US-4138490-A | Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361059-A1 | SUBSTITUTED HETERO-AZEPINONES | CCNY, CCNE1, CCND3 | LMNA 2738/4885KEAP1 2495/4885NFE2L2 2547/4885 |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | LMNA 748/4885KEAP1 555/4885NFE2L2 315/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | LMNA 748/4885KEAP1 555/4885NFE2L2 315/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | LMNA 792/4885KEAP1 1335/4885NFE2L2 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.